AIM Announces 2018 Sustainability Award Winners
BSM is thrilled to have won the 2018 Associated Industries of Massachusetts (AIM) Sustainability Award! We hope to continue our growth as a company as we relentlessly strive to produce the most sterile products achievable.
Seven Massachusetts companies ranging from a global financial-services powerhouse to a startup Berkshire County drug manufacturer have been named winners of the third annual Associated Industries of Massachusetts (AIM) Sustainability Award. The award recognizes excellence in environmental stewardship, promotion of social well-being and contributions to economic prosperity.
AIM announced today that State Street Corporation and Eversource of Boston; Analog Devices of Wilmington; Fallon Health of Worcester; Sanderson MacLeod Inc. of Palmer; Berkshire Sterile Manufacturing of Lee; and Twin Rivers Technologies of Quincy were selected from among several dozen nominations. The seven companies will be honored at a series of regional celebrations throughout Massachusetts during September, October and November.
“These companies set the standard for sustainability managing their financial, social and environmental resources in a manner that ensures responsible, long-term success,” said AIM President and Chief Executive Officer Richard C. Lord.
“Sustainability guarantees that the success of employers benefits our communities, our commonwealth and our fellow citizens. We congratulate our honorees and all the worthy companies that were nominated.”
Sustainability has gained widespread acceptance in recent years as global corporations such as Wal-Mart, General Electric and IBM make it part of their business and financial models.
The seven honorees were selected by a committee that included members of the AIM Sustainability Roundtable, along with experts Wayne Bates PhD., PE, Principal Engineer for Tighe & Bond, Inc.; Matt Gardner, Managing Partner Sustainserv; and Cristina Mendoza, Solutions Design Lead for Capaccio Environmental.
AIM initiated the Sustainability Roundtable in 2011 to provide employers the opportunity to exchange sustainability best practices and hear from experts in the field. That opportunity has attracted hundreds of participants ranging from companies such as Bose, Coca-Cola, Boston Beer, Ocean Spray and Analogic to smaller businesses such as RH White and Precision Engineering.
Berkshire Sterile Manufacturing, Inc.| October 25 | Hotel on North | Pittsfield
What if you could create a sustainable, sterile drug manufacturing facility from the ground up?
Chances are that it would look a lot like Berkshire Sterile Manufacturing, a three-year-old startup that specializes in manufacturing small-scale injectable drugs for clinical trials with an isolator that ups the quality of the clean-room product.
Berkshire Sterile describes itself as a state-of-the-art fill/finish contract manufacturer providing formulation and sterile filling as well as analytical development and stability services to the biotech and pharmaceutical industries. All sterile filling operations at BSM are performed utilizing isolator-based technology.
BSM also offers terminal steam sterilization of syringes, specialty filling and lyophilization of vials and syringes including dual chamber liquid/liquid and liquid/lyo configurations.
It’s an operation that is generating significant economic growth in the Berkshires.
The company has hired more than 80 professional positions in the past 3.5 years. More than 10 of those employees have purchased houses in the area. Clients come from all over the US and overseas to visit the facility, bringing a lot of business to local hotels and restaurants
BSM worked with several suppliers of pharmaceutical manufacturing equipment to design and produce an isolator-based manufacturing line that could produce sterile injectable drug products in vials, syringes and cartridges. A flexible design of the system allows multiple drug container types to be filled in the same manufacturing line. The drugs that BSM produces are primarily new drugs in development and clinical trials to treat various therapeutic areas including cancer, osteoarthritis, cardiac diseases and pediatric orphan diseases.
The use of isolator technology not only provides better assurance of drug sterility, it reduces requirements for large volumes of heating, cooling and dehumidification/humidification required for traditional cleanroom environments. The technology also reduces the requirements for sterile gowning and testing reducing trash and consuming fewer valuable resources.